SI-BONE, Inc.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
SIBN$25.10-2.0%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 8. Consolidated Statements of Cash Flows
(In thousands)
| Year Ended December 31, | |||
|---|---|---|---|
| 2025 | 2024 | 2023 | |
| Cash flows from operating activities | |||
| Net loss | $(18,904) | $(30,913) | $(43,336) |
| Adjustments to reconcile net loss to net cash used in operating activities | |||
| Stock-based compensation | 25,524 | 25,869 | 24,057 |
| Depreciation and amortization | 5,770 | 4,379 | 5,428 |
| Accounts receivable credit losses | 570 | 470 | 761 |
| Inventory reserve | 1,997 | 1,300 | 1,709 |
| Amortization of discount and premium on marketable securities | (3,051) | (5,440) | (4,009) |
| Amortization of debt issuance costs | 117 | 153 | 208 |
| Loss on disposal of property and equipment | 1,627 | 1,877 | 1,302 |
| Changes in operating assets and liabilities | |||
| Accounts receivable | (3,027) | (5,840) | (2,122) |
| Inventory | (8,684) | (8,047) | (4,719) |
| Prepaid expenses and other assets | (1,030) | (2) | (762) |
| Accounts payable | (1,763) | 1,861 | (1,118) |
| Accrued liabilities and other | 179 | 1,908 | 3,888 |
| Net cash used in operating activities | (675) | (12,425) | (18,713) |
| Cash flows from investing activities | |||
| Maturities of marketable securities | 205,100 | 228,500 | 137,500 |
| Purchases of marketable securities | (192,526) | (205,380) | (189,499) |
| Purchases of property and equipment | (8,414) | (10,497) | (7,799) |
| Net cash provided by (used in) investing activities | 4,160 | 12,623 | (59,798) |
| Cash flows from financing activities | |||
| Proceeds from follow-on public offering, net of underwriting discounts, commissions and offering costs | — | — | 83,671 |
| Proceeds from debt financing, net of debt issuance cost | — | 35,954 | 35,960 |
| Repayments of debt financing | — | (36,000) | (35,275) |
| Final payment fee related to debt | — | (720) | — |
| Proceeds from the exercise of common stock options | 1,169 | 570 | 4,386 |
| Proceeds from issuance of common stock under employee stock purchase plan | 2,207 | 2,154 | 2,191 |
| Net cash provided by financing activities | 3,376 | 1,958 | 90,933 |
| Effect of exchange rate changes on cash and cash equivalents | 431 | (479) | 132 |
| Net increase in cash and cash equivalents | 7,292 | 1,677 | 12,554 |
| Cash and cash equivalents at | |||
| Beginning of year | 34,948 | 33,271 | 20,717 |
| End of year | $42,240 | $34,948 | $33,271 |
| Supplemental disclosure of cash flow information | |||
| Cash paid for interest | $2,533 | $3,346 | $3,263 |
| Noncash investing and financing activities | |||
| Operating lease right-of-use assets obtained in exchange for operating lease liabilities | $251 | $449 | $143 |
| Supplemental disclosure of non-cash information | |||
| Unpaid purchases of property and equipment | $495 | $588 | $501 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.